The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.

The present invention relates to compositions, kits and methods for making and using RNA compositions comprising in vitro-synthesized ssRNA inducing a biological or biochemical effect in a mammalian cell or organism into which the RNA composition is repeatedly or continuously introduced. In certain embodiments, the invention provides compositions and methods for changing the state of differentiation or phenotype of a human or other vertebrate cell. For example, the present invention provides mRNA and methods for reprogramming cells that exhibit a first differentiated state or phenotype to cells that exhibit a second differentiated state or phenotype, such as to reprogram human somatic cells to pluripotent stem cells.

A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza may be characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.

Provided herein are compositions and methods for the inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C) expression and/or activity, and treatment or prevention of inflammation therewith.

CD47− disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

Provided is a use of an agent for regulating an amino acid level in preparing a drug for treating Alzheimer's disease in a subject.

This invention relates to inhibitors of CXC receptor 4 (CXCR4)-G protein-coupled receptor (GPCR) heteromers (CXCR4-GPCR heteromers) associated with cancers, where CXCR4 forms a functional heteromer with other G protein-coupled receptors (GPCRx). More specifically, this invention relates to ADRB2 that form heteromers with CXCR4, which upon co-stimulation with CXCR4 agonists and ADRB2 agonists leads to enhanced signaling downstream of CXCR4. This invention also provides for pharmaceutical compositions and kits comprising a CXCR4 inhibitor and an ADRB2 inhibitor, and methods for treating and using the same, and in the diagnosis and/or therapy for cancer.

The present invention relates to a method for treating a neurological disease in a subject including administering to the subject a pharmaceutical composition of a eukaryotic elongation factor 2 kinase (eEF2K)-inhibiting compound.

Methods of inducing apoptosis and inhibiting proliferation in YAP-dependent cancer cells, involving contacting the cells with one or more inhibitors of YAP and one or more inhibitors of SOX2. In addition, methods of treating or preventing YAP-dependent cancer in subjects, involving administering to the subject one or more inhibitors of YAP and one or more inhibitors of SOX2.

Described herein are compositions and methods that include use of PERK inhibitors, inhibitors of enzymes that can synthesize lysophosphatidic acid (LPA), inhibitors of LPA signaling, such as LPA receptor antagonists, deletion/mutation knockout/knock-down) or PERK or LPA receptors, or combinations thereof. Such compositions and methods can increase production of interferon by dendritic cells in subjects suffering from cancer and improve the survival of those subjects.